Shares of Roivant Sciences have moved 0.4% today, and are now trading at a price of $20.98. In contrast, the S&P 500 index saw a 0.0% change. Today's trading volume is 778,939 compared to the stock's average volume of 8,111,542.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Based in London, United Kingdom the company has 750 full time employees and a market cap of $14,587,935,744.
The company is now trading -5.05% away from its average analyst target price of $22.09 per share. The 11 analysts following the stock have set target prices ranging from $16.0 to $29.0, and on average give Roivant Sciences a rating of buy.
Over the last 52 weeks, ROIV stock has risen 74.9%, which amounts to a 60.5% difference compared to the S&P 500. The stock's 52 week high is $21.35 whereas its 52 week low is $8.73 per share. Based on Roivant Sciences's average net margin growth of 29.5% over the last 5 years, its core business is on track for profitability and its strong stock performance may continue in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) |
|---|---|---|---|
| 2024 | 29,053 | -171,981 | -592 |
| 2023 | 32,713 | 4,348,926 | |
| 2022 | 31,530 | -1,009,030 | -3200 |
| 2021 | 55,286 | -845,262 | -1529 |
| 2020 | 23,795 | -809,234 | -3401 |
